Within the framework of prospective clinical trials, the authors systematically collected paired sequencing data from tumor biopsies and circulating cell-free DNA to identify patients with drug resistance that was not attributable to TRK kinase domain mutations. This evidence concerns the gene NTRK1 and neoplasm.